RxDoctor Payments Data

Mark Pedigo, PA

Physician Assistant · Denton, TXNPI 1144798570

Payments from drug & device makers

$12,326in general payments, 2019–2025

Across 731 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Bayer$566
  • Lilly USA, LLC$565
  • GSK$550
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,26499%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk91$1,458
AstraZeneca78$1,291
AbbVie82$1,272
Bayer36$566
Lilly USA, LLC36$565
GSK28$550
Amgen39$530
Otsuka America Pharmaceutical, Inc.24$490
Pfizer25$449
Boehringer Ingelheim26$422
Johnson & Johnson29$418
Astellas Pharma US Inc14$304
Novartis13$303
Sanofi-aventis U.S. LLC15$303
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$261
Exact Sciences15$235
Dexcom, Inc.13$232
Antares Pharma, Inc.11$228
Merck12$198
Lundbeck LLC14$197
Corcept Therapeutics10$193
Takeda Pharmaceuticals U.S.A., Inc.9$186
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$167
Phathom Pharmaceuticals, Inc.9$156
Axsome Therapeutics, Inc.5$130
Sumitomo Pharma America, Inc.6$105
Nevro Corp.5$93
Sanofi Pasteur Inc.5$77
Alnylam Pharmaceuticals Inc.3$55
Aimmune Therapeutics, Inc.3$52
Radius Health, Inc.3$52
Esperion Therapeutics, Inc.3$50
Abbott2$40
Teva Pharmaceuticals USA, Inc.2$38
Dynavax Technologies Corporation2$37
Eisai Inc.2$36
Biogen2$33
Nestle Healthcare Nutrition Inc.2$33
Amarin Pharma, Inc.2$28
Biohaven Pharmaceutical Holding Company Ltd.2$27
Currax Pharmaceuticals LLC2$27
Genentech USA, Inc.3$27
Inari Medical, Inc.1$26
Mylan Specialty L.p.1$25
Xeris Pharmaceuticals, Inc.1$25
Inspire Medical Systems, Inc.1$25
Shield Therapeutics Inc1$25
Seqirus USA Inc1$23
Amneal Pharmaceuticals LLC1$22
Tris Pharma Inc1$22
Recordati_rare_diseases_inc.1$20
Sunovion Pharmaceuticals Inc.1$20
Pacira Pharmaceuticals Incorporated1$19
Acella Pharmaceuticals, LLC1$18
Corium, LLC1$16
IBSA Pharma Inc.1$16
Boston Scientific1$16
Phadia US Inc.1$16
Optinose US, Inc.1$15
Ironwood Pharmaceuticals, Inc1$14

How this compares

$12,326 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$69,390
Medicare patients
294
Services billed
1,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$96,995
JardianceEmpagliflozin70$73,116
MounjaroTirzepatide48$67,816
FarxigaDapagliflozin Propanediol22$31,181
EliquisApixaban26$23,060
Repatha SureclickEvolocumab16$22,479
Soliqua 100-33Insulin Glargine/Lixisenatide16$18,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,390
ElmironPentosan Polysulfate Sodium12$9,605
MyrbetriqMirabegron13$9,422
LinzessLinaclotide11$9,256
JanuviaSitagliptin Phosphate12$8,224
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,833
Atorvastatin Calcium297$2,932
Rosuvastatin Calcium167$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,458$96,99560 claims
Boehringer IngelheimJardiance$422$73,11670 claims
Lilly USA, LLCMounjaro$565$67,81648 claims
AstraZenecaFarxiga$1,291$31,18122 claims
PfizerEliquis$449$23,06026 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$303$18,93916 claims
GSKTrelegy Ellipta$550$17,39027 claims
AbbVieLinzess, Synthroid$1,272$10,65138 claims
Astellas Pharma US IncMyrbetriq$304$9,42213 claims
MerckJanuvia$198$8,22412 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$1,582146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →